ZENITH20, a multicenter, multicohort phase II clinical trial, was designed to evaluate the efficacy and safety of poziotinib in NSCLC patients with EGFR or HER2 ex20ins mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.